Hikal swings to a loss as USFDA issues and impairments bite
The company reported a net loss of ₹487 million for FY26, down from a profit of ₹909 million, while slashing its dividend payout by more than half.
— 3 earlier stories on Hikal Ltd. →What's new
- Revenue dropped 8% to ₹17.1 billion for the fiscal year.
- A ₹471 million impairment charge was booked for plant repurposing.
- The board cut the total dividend payout to 30% from 70%.
Why this matters
The combination of a USFDA warning letter at the Jigani facility and ongoing Supreme Court environmental litigation creates significant operational and legal uncertainty. Cutting the dividend payout by over half signals that management expects these headwinds to persist.
What we're watching
- Resolution of the USFDA warning letter at the Jigani facility.
- Updates on the Supreme Court environmental litigation.
- Evidence of recovery in the pharmaceutical segment.
The full read
Hikal’s FY26 results show a sharp deterioration in performance. The company swung to a net loss of ₹487 million from a profit of ₹909 million the previous year. Revenue fell 8% to ₹17.1 billion, hampered by a USFDA warning letter at the Jigani facility.
It was a difficult year.
A ₹471 million impairment charge, taken to repurpose a manufacturing plant, further weighed on the bottom line. Management responded by cutting the total dividend payout to 30% from 70%, signaling a defensive stance while they navigate an unresolved environmental case before the Supreme Court that adds a layer of uncertainty to the company's future prospects.
Questions answered
- What drove the swing to a net loss in FY26?
- Hikal posted a net loss of ₹487 million due to an 8% revenue decline and a one-time impairment charge of ₹471 million related to repurposing a manufacturing plant.
- How did the USFDA warning letter affect the company?
- The warning letter at the Jigani facility impacted the pharmaceutical segment's performance, contributing to the overall revenue decline.
- What is the status of the dividend payout?
- The board recommended a final dividend of ₹0.40 per share, bringing the total payout for the year to 30% of the dividend, down from 70% in the previous year.
- Are there other legal risks mentioned?
- Yes, the company faces ongoing environmental litigation before the Supreme Court, which remains unresolved and carries an emphasis of matter.
Story so far
All notes on HIKAL →- 27 May 2026 · 4:07 PM IST Hikal swings to a loss as USFDA issues and impairments bite
- today Hikal's earnings release adds no new data to prior disclosures.
- today Hikal's latest investor presentation adds no new information
- today Hikal fills key division vacancy and closes internal probe